Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
Similar News
expand_more
3 w.
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
Science
Technology
Science
Technology